File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: An Effective Interleukin-2 Cancer Immunotherapy Delivered by a Novel Polymeric nanoparticle in Melanoma

TitleAn Effective Interleukin-2 Cancer Immunotherapy Delivered by a Novel Polymeric nanoparticle in Melanoma
Authors
Issue Date2009
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.immunotherapy-journal.com
Citation
International Society for Biological Therapy of Cancer 24th Annual Meeting, Washington, DC, 28-31 October 2009, v. 32 n. 9, p. 965 How to Cite?
AbstractInterleukin-2 (IL-2) has been shown to possess antitumor activity in numerous preclinical and clinical studies. However, the short half-life of recombinant IL-2 protein in serum requires repeated high doses administration, resulting in severe side effects. Although adenovirus-mediated hIL-2 gene therapy has shown antitumor efficacy, the host antibody response to adenoviral particles and potential biosafety misgivings prevented its clinical application. Here we report a novel polymer, consisting of low-molecular weight Polyethylenimine (PEI 600 Da) linked by Cyclodextrin and conjugated with Folate (referred to as H1). The H1 assembled hIL- 2 plasmid to form H1/phIL-2 polyplexes with size around 100 nm. Peritumoral injection of these polyplexes suppressed the tumor growth and prolonged the survival in C57/BL 6 mice bearing B16- F1 cells. Importantly, the antitumor effects of H1/hIL-2 plasmid (DNA 50 mg) were similar to those of Adv-hIL-2 (2 108 pfu). Furthermore, we showed that this treatment activated immune cells such as cytotoxic T lymphocyte and natural killer cells. Interestingly, it has no effect on the number of CD4+CD25+ Treg cells of peripheral blood, which was reported to suppress antitumor immune responses. In conclusion, these results showed that H1/ phIL-2 polyplexes are an effective and safe therapy with an efficacy comparable to that of Adv-hIL-2. This treatment represents an alternative gene therapy strategy for melanoma.
Persistent Identifierhttp://hdl.handle.net/10722/97576
ISSN
2015 Impact Factor: 3.712
2015 SCImago Journal Rankings: 2.165

 

DC FieldValueLanguage
dc.contributor.authorYao, H-
dc.contributor.authorLi, M-
dc.contributor.authorNg, SM-
dc.contributor.authorLin, MC-
dc.date.accessioned2010-09-25T17:14:11Z-
dc.date.available2010-09-25T17:14:11Z-
dc.date.issued2009-
dc.identifier.citationInternational Society for Biological Therapy of Cancer 24th Annual Meeting, Washington, DC, 28-31 October 2009, v. 32 n. 9, p. 965-
dc.identifier.issn1524-9557-
dc.identifier.urihttp://hdl.handle.net/10722/97576-
dc.description.abstractInterleukin-2 (IL-2) has been shown to possess antitumor activity in numerous preclinical and clinical studies. However, the short half-life of recombinant IL-2 protein in serum requires repeated high doses administration, resulting in severe side effects. Although adenovirus-mediated hIL-2 gene therapy has shown antitumor efficacy, the host antibody response to adenoviral particles and potential biosafety misgivings prevented its clinical application. Here we report a novel polymer, consisting of low-molecular weight Polyethylenimine (PEI 600 Da) linked by Cyclodextrin and conjugated with Folate (referred to as H1). The H1 assembled hIL- 2 plasmid to form H1/phIL-2 polyplexes with size around 100 nm. Peritumoral injection of these polyplexes suppressed the tumor growth and prolonged the survival in C57/BL 6 mice bearing B16- F1 cells. Importantly, the antitumor effects of H1/hIL-2 plasmid (DNA 50 mg) were similar to those of Adv-hIL-2 (2 108 pfu). Furthermore, we showed that this treatment activated immune cells such as cytotoxic T lymphocyte and natural killer cells. Interestingly, it has no effect on the number of CD4+CD25+ Treg cells of peripheral blood, which was reported to suppress antitumor immune responses. In conclusion, these results showed that H1/ phIL-2 polyplexes are an effective and safe therapy with an efficacy comparable to that of Adv-hIL-2. This treatment represents an alternative gene therapy strategy for melanoma. -
dc.languageeng-
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.immunotherapy-journal.com-
dc.relation.ispartofJournal of Immunotherapy-
dc.rightsThis is a non-final version of an article published in final form in (provide complete journal citation)-
dc.titleAn Effective Interleukin-2 Cancer Immunotherapy Delivered by a Novel Polymeric nanoparticle in Melanoma-
dc.typeConference_Paper-
dc.identifier.emailNg, SM: ssmng@hku.hk-
dc.identifier.emailLin, MC: mcllin@HKUCC.hku.hk-
dc.identifier.authorityNg, SM=rp00767-
dc.identifier.authorityLin, MC=rp00746-
dc.identifier.doi10.1097/CJI.0b013e3181bbeb58-
dc.identifier.hkuros167737-
dc.identifier.volume32-
dc.identifier.issue9-
dc.identifier.spage965-
dc.identifier.epage965-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats